Phase I trial of the first-in-class EGFR antibody mixture, Sym004, in patients with advanced solid tumors.
暂无分享,去创建一个
A. Tolcher | R. Dienstmann | D. Rasco | A. Patnaik | I. Braña | K. Papadopoulos | A. Piera | J. Tabernero | N. Skartved | H. Aladdin | J. Petersen